clock.bio

We are looking for a lead bioinformatician to join our clock.bio team in Cambridge. This will be an exciting opportunity to co-shape our analytics work on a novel and unique set of data. Details below - feel free to share! https://lnkd.in/eik3uymG

We are looking for a lead bioinformatician to join our clock.bio team in Cambridge. This will be an exciting opportunity to co-shape our analytics work on a novel and unique set of data. Details below - feel free to share! https://lnkd.in/eik3uymG

Great opportunity at clock.bio! #Hiring #Bioinformatics https://lnkd.in/eik3uymG

We are delighted to announce that clock.bio is a finalist in the 'One to watch' category in the Cambridge Independent Science and Technology Awards 2024 Kudos to all the remarkable nominees! 🌟 We look forward to the ceremony on Thursday, 16th May. Stay tuned! #Innovation #Recognition #CambridgeAwards #ScienceAndTechnology #Biotech #Longevity #Health #lifescience #technology #science #research #Cambridge

We have now made it to the shortlist of #21toWatch! #longevity #biotech #startupsuccess #cambridge #healthspan

Great article summarizing some recent trends on aging research: https://lnkd.in/e5U25qBm "The blossoming of aging research is a big shift from when he started to work on aging 12 years ago", says Benitah. Gone are the days of small meetings and researchers working in disparate disciplines such as stem cell science or physiology. He says of aging research, "Now, it’s huge."

Excited to see our co-founder Mark Kotter speak at Biotech Showcase at JPM in January!

𝐀𝐮𝐠𝐮𝐬𝐭’𝐬 𝐦𝐚𝐢𝐧 𝐟𝐮𝐧𝐝𝐢𝐧𝐠 𝐫𝐨𝐮𝐧𝐝𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐈𝐧𝐝𝐮𝐬𝐭𝐫𝐲 I know you were waiting for this, and I know it took longer than usual. I promise, it’s going to be worth the wait: we got some interesting raisers during last month, so let’s get into it! 🇺🇲 The top five privately-raised funds in the US were Series B to C (no Series A in sight 👀) Namely: - ADARx Pharmaceuticals Inc.: 200M$ raised in Series C to advance RNA therapeutics aimed at cardiovascular, metabolic, and CNS diseases. One to watch out for, if I may say so! - Genesis Therapeutics: also bagged 200M$ in Series B to bring its first AI-enabled drug candidate into the clinic. - Kyverna Therapeutics secured 145M$ in Series B for cell therapy aimed at treating autoimmune and inflammatory disorders: this one I first heard of from none other than the excellent Spencer Knight! 🇪🇺 Now, let’s have a look at who raised how much on this side of the pond. 𝑵𝑩: the numbers are SIGNIFICANTLY less important, however here is where we find most of last month’s Series As, which are dwindling in frequency industry-wide. - ACTIMED THERAPEUTICS: 6M$ raised in Series A for metabolic disorders, for this UK based emerging biotech. - VRG Therapeutics: this Hungary-based company raised 5M$ in Series A to fund their metabolic disease drug development; - clock.bio: brought in 4M$ in Private Equity funds to pursue research on age-related disorders; this is one company I’m particularly interested in, for my own special interests in neuroscience and chronobiology! 😀 🇨🇳 Again, a special mention to the highest raiser in APAC: China-based Neurophth Therapeutics / 纽福斯生物科技有限公司, who raised 95M$ in Series C to advance the clinical stage of their ophthalmology gene therapy. A few interesting points to look at here: 1️⃣ Cell & Gene and RNA therapeutics are gathering momentum as well as funding; 2️⃣ Ophthalmology and metabolic disorders are still amongst the fastest runners; 3️⃣ Series A funding keeps declining, in numbers as well as in frequency… I’ll come back to this in a future post, so stay tuned. * What do 𝑦𝑜𝑢 think is the main take-home message from August's main funding rounds? Or are there any other successful fundraisers not mentioned here that grabbed your attention? Let me know and let’s continue the discussion in the comments 👇🏻! * I’m 𝐂𝐥𝐚𝐮𝐝𝐢𝐚, founder of Sichem Bio, Pitch Perfectionist and Market Maven, and I’m here to facilitate transactions. In short: I’m a Business Advisor on a mission to empower the Biotech industry! Hit the 🔔 button to follow my feed, or click on the link in my profile to book a chat!